Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial
Christian U. Blank, Lotte Hoeijmakers, Petros Dimitriadis, S C M A Wijnen, Irene L. M. Reijers, Marta López‐Yurda, Alexander M. Menzies, Annegien Broeks, Sten Cornelissen, Alex Torres Acosta, Anja van der Wal, Robyn P.M. Saw, Judith M. Versluis, Winan J. van Houdt, Michel W.J.M. Wouters, Jurriaan Romano, Elisa A. Rozeman, L. Grijpink-Ongering, Ellen Kapiteijn, Astrid van der Veldt, Karijn P.M. Suijkerbuijk, Hanna Eriksson, Geke A.P. Hospers, Jos A. van der Hage, Dirk J. Grünhagen, Arjen J. Witkamp, Judith Lijnsvelt, W. Martin C. Klop, Charlotte L. Zuur, Annemarie Bruining, Abrahim Al-Mamgani, Thomas E. Pennington, Kerwin F. Shannon, Sydney Ch’ng, Andrew J. Colebatch, Maria Gonzalez, Andrew Spillane, John B.A.G. Haanen, Robert V. Rawson, Richard A Scolyer, Bart A. van de Wiel, Alexander C.J. van Akkooi, Georgina V. Long (2025). Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial. , DOI: https://doi.org/10.21203/rs.3.rs-7090131/v1.
Preprint54 days ago1614P Long-term outcome of adding the histone deacetylase inhibitor (HDACi) domatinostat (DOM) to neoadjuvant (neoadj) nivolumab (NIVO) +/- ipilimumab (IPI) in interferon-gamma signature (IFNγ) high/low stage III melanoma patients (pts)
Lianne Hoeijmakers, Irene L. M. Reijers, A.M. Menzies, Petros Dimitriadis, Marta López‐Yurda, Sten Cornelissen, Michel W.J.M. Wouters, R. Saw, M. Klop, Thomas E. Pennington, W. Van Houdt, L.J.W. Bosch, L. Grijpink-Ongering, R. Rawson, Andrew J. Spillane, Richard A Scolyer, B. van de Wiel, Alexander C.J. van Akkooi, G.V. Long, C.U. Blank (2025). 1614P Long-term outcome of adding the histone deacetylase inhibitor (HDACi) domatinostat (DOM) to neoadjuvant (neoadj) nivolumab (NIVO) +/- ipilimumab (IPI) in interferon-gamma signature (IFNγ) high/low stage III melanoma patients (pts). , 36, DOI: https://doi.org/10.1016/j.annonc.2025.08.2242.
Article54 days ago1090P High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma
Lianne Hoeijmakers, Petros Dimitriadis, Sten Cornelissen, Irene L. M. Reijers, B. van de Wiel, Richard A Scolyer, R.P.M. Saw, Andrew J. Spillane, A. Broeks, Marta López‐Yurda, L. Grijpink-Ongering, G. Hospers, Alexander M. Menzies, Alexander C.J. van Akkooi, W. Van Houdt, G.V. Long, Christian U. Blank (2024). 1090P High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma. , 35, DOI: https://doi.org/10.1016/j.annonc.2024.08.1158.
Article54 days agoRevisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.
Minke W. Lucas, Petros Dimitriadis, Irene L. M. Reijers, Alexander M. Menzies, Elisa A. Rozeman, Judith M. Versluis, Alexander C. Huang, Sten Cornelissen, Annegien Broeks, Richard A Scolyer, Tara C. Mitchell, Georgina V. Long, Christian U. Blank (2023). Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.. , 41(16_suppl), DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9516.
Article54 days ago1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Irene L. M. Reijers, Petros Dimitriadis, Alexander M. Menzies, Ellen Kapiteijn, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk, Geke A.P. Hospers, Winan J. van Houdt, Robyn P.M. Saw, Annegien Broeks, Sten Cornelissen, Lindsay G. Grijpink-Ongering, Thomas E. Pennington, Andrew J. Colebatch, B. van de Wiel, Richard A Scolyer, Alexander C.J. van Akkooi, Georgina V. Long, Christian U. Blank (2023). 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma. , 34, DOI: https://doi.org/10.1016/j.annonc.2023.09.2229.
Article54 days ago